Purified anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_Pure_021706
BALB/c mouse splenocytes were stained with purified CD4 (clone GK1.5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC.
  • GK1dot5_Pure_021706
    BALB/c mouse splenocytes were stained with purified CD4 (clone GK1.5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC.
Compare all formats
Cat # Size Price Quantity Check Availability Save
100401 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100402 500 µg 62€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, IP - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  2. Chami B, et al. 2017. Sci Rep. 7:10181. PubMed
  3. Tsukumo S, et al. 2006. J Immunol. 177:8365. PubMed
  4. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  5. Liao X, et al. 2022. Front Immunol. 12:768813. PubMed
  6. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  7. Smith CJ, et al. 2018. J Immunol. 200:1580. PubMed
  8. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  9. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  10. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  11. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  12. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  13. Shirakawa K, et al. 2017. PLoS One. 12:e0186303. PubMed
  14. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  15. Fernandes V, et al. 2020. PLoS Pathog. 16:e1008464. PubMed
  16. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  17. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  18. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  19. Hummel JF, et al. 2020. Mucosal Immunol. 0.720138889. PubMed
  20. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  21. Duvvuri M, et al. 2019. Biomater Sci. 7:1863. PubMed
  22. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  23. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
  24. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  25. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
  26. Hashimoto K, et al. 2021. J Dermatol Sci. 102:177. PubMed
  27. Haque M, et al. 2021. Viruses. 13:. PubMed
  28. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  29. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
  30. Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  31. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  32. Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed
  33. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  34. Xie MM, et al. 2017. Eur J Immunol. 47:1136. PubMed
  35. Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed
  36. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  37. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  38. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
  39. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  40. Tan L, et al. 2017. Int J Nanomedicine. 12:3095. PubMed
  41. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  42. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  43. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  44. Lasrado N, et al. 2021. Microorganisms. 9:. PubMed
  45. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  46. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  47. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  48. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  49. Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed
  50. Skeate JG, et al. 2018. PLoS One. 13:e0191311. PubMed
  51. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  52. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  53. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  54. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  55. Sharma M, et al. 2020. Nat Commun. 11:661. PubMed
  56. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  57. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
  58. Elsayed H, et al. 2018. J Virol. 92:e00428. PubMed
  59. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  60. Hu M, et al. 2008. J Immunol. 180:6593. PubMed
  61. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  62. Shokirova H, et al. 2021. Sci Rep. 11:8647. PubMed
  63. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  64. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  65. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  66. Horiuchi S, et al. 2021. Sci Immunol. :eabm3131. PubMed
  67. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
  68. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  69. Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed
  70. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  71. Liu M, et al. 2018. Diabetologia. 61:2333. PubMed
  72. Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed
  73. Majer O, et al. 2019. Nature. 575:366. PubMed
  74. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  75. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  76. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  77. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  78. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
  79. Zhang H, et al. 2017. J Immunol. 198:2133. PubMed
  80. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  81. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  82. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  83. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  84. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  85. Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed
  86. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
  87. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  88. Chen X, et al. 2019. Methods Mol Biol. 2048:131. PubMed
  89. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
  90. Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed
  91. Floudas A, et al. 2017. J Immunol. 199:707. PubMed
  92. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  93. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  94. Pradhan P, et al. 2017. JCI Insight. 2. PubMed
  95. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  96. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  97. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
  98. Wilhelmson AS, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1519. PubMed
  99. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  100. Stefanski HE, et al. 2018. PLoS One. 13:e0198871. PubMed
  101. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  102. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  103. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  104. Rosenberg J, et al. 2020. Cell Systems. 10(5):433-444. PubMed
  105. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
  106. Liu J, et al. 2022. Stem Cell Res Ther. 13:247. PubMed
  107. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  108. Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed
  109. Luu M, et al. 2019. Nat Commun. 10:760. PubMed
  110. Di Dalmazi G, et al. 2019. J Immunol. 202:1350. PubMed
  111. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
  112. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  113. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  114. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  115. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
  116. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  117. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
  118. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  119. Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  120. Whittle JR, et al. 2020. Clin Cancer Res. 26:4120. PubMed
  121. Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed
  122. Krämer TJ, et al. 2019. J Neuroinflammation. 16:163. PubMed
  123. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  124. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  125. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  126. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  127. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
RRID
AB_312686 (BioLegend Cat. No. 100401)
AB_312687 (BioLegend Cat. No. 100402)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV™ 395 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account